Cargando…

B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide

Detalles Bibliográficos
Autores principales:	Thiel, Jens, Effelsberg, Nora M, Warnatz, Klaus, Schlesier, Michael, Peter, Hans Hartmut, Voll, Reinhard E, Venhoff, Nils
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242264/ http://dx.doi.org/10.1186/1479-5876-9-S2-P36

Ejemplares similares

Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
por: Venhoff, Nils, et al.
Publicado: (2012)

CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1
por: Zeisbrich, Markus, et al.
Publicado: (2021)

Favourable outcome of acute hepatitis E infection in patients with ANCA-associated vasculitis
por: Zeisbrich, Markus, et al.
Publicado: (2022)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients
por: Thiel, Jens, et al.
Publicado: (2017)

Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
por: Thiel, Jens, et al.
Publicado: (2013)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis
por: Lundberg, Sigrid, et al.
Publicado: (2017)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study
por: Ysermans, Renée, et al.
Publicado: (2022)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
por: Treppo, Elena, et al.
Publicado: (2021)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial
por: Maritati, Federica, et al.
Publicado: (2017)

Mitochondrial DNA: a novel indicator of active inflammation in ANCA-associated vasculitides
por: Giaglis, Stavros, et al.
Publicado: (2023)

Blood CD3-(CD56 or 16)+ natural killer cell distributions are heterogeneous in healthy adults and suppressed by azathioprine in patients with ANCA-associated vasculitides
por: Merkt, Wolfgang, et al.
Publicado: (2021)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

Case Report: Effective and Safe Treatment With Certolizumab Pegol in Pregnant Patients With Cogan’s Syndrome: A Report of Three Pregnancies in Two Patients
por: Venhoff, Nils, et al.
Publicado: (2021)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis
por: Kant, Sam, et al.
Publicado: (2019)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
por: Harris, Claire, et al.
Publicado: (2018)

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021)

Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: A comparative cohort study
por: Speer, Claudius, et al.
Publicado: (2021)

Respiratory tract infections and risk factors for infection in a cohort of 330 patients with axial spondyloarthritis or psoriatic arthritis
por: Frede, Natalie, et al.
Publicado: (2022)

Analysis of Specific IgG Titers Against Tick-Borne Encephalitis in Patients with Primary Antibody Deficiency Under Immunoglobulin Substitution Therapy: Impact of Plasma Donor Origin
por: Goldacker, Sigune, et al.
Publicado: (2015)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

ANCA‐associated vasculitis with scleritis, corneal melt, and perforation rescued by rituximab: Case report and literature review
por: Matsuo, Toshihiko, et al.
Publicado: (2023)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening Eosinophilic Granulomatosis With Polyangiitis
por: Schramm, Markus A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sp22ua51r0b1lvq6880uhv4p2k